

ARCHIVOS DE Bronconeumología



www.archbronconeumol.org

Clinical Letter

Interstitial Lung Disease Caused by Apalutamide for Metastatic Castration-Sensitive Prostate Cancer

Apalutamide is an androgen receptor signaling inhibitor (ARSi), indicated as standard of care in 2019 in the treatment of metastatic castration-sensitive prostate cancer (mCSPC) together with androgen deprivation therapy (ADT).¹ The incidence of interstitial lung disease (ILD) associated with apalutamide is very uncommon with few cases of this side effect reported on the literature.^{2–4} ILD can become serious so clinicians should be alerted to this potential adverse effect and know the clinical management in this situation. Here, we present two cases of apalutamide-induced interstitial lung disease who were successfully treated with high-dose corticosteroids.

The first case refers to a 55-year-old man without medical history of interest diagnosed of metachronous low volume mCSPC. He initiated Triptorelin 22.5 mg and a month later initiated apalutamide. The dose of apalutamide was reduced from 240 mg to 180 mg per day after two months due to the appearance of grade III skin rash. One month later, the patient experienced cough and progressive respiratory distress. On auscultation, fine crackles were heard in both lungs. Chest CT showed subpleural parenchymal bands, ground-glass opacities and bilateral consolidations (Fig. 1A), without alterations in previous imaging test. Based on these findings and on the absence of any other suspected drug, the diagnosis of apalutamide-induced ILD was made, so apalutamide was discontinued and endovenous metilprednisolone 1 mg/kg/day was started. After five days, the treatment was switched to oral deflazacort 80 mg/day for seven days, progressively reducing 20 mg per week until discontinued. The patient improved his respiratory status after 15 days of corticosteroids treatment. Chest-CT at 3 months after discontinuing apalutamide, showed a significant improvement with resolution of previously described pulmonary signs (Fig. 1B).

The second case refers to a 73-year-old man without medical history of interest diagnosed "de novo" mCSPC and treated with radiotherapy to the prostate as well as leuprorelin 45 mg and apalutamide (240 mg/day). Six months after initiation of apalutamide he described an evolution of two months of cough, mucous expectoration and weight loss, the patient was admitted to pneumology due to clinical worsening and acute respiratory failure. Chest-CT showed bilateral patchy areas of ground-glass opacities with bronchiectasis (Fig. 2A), without alterations in previous imaging test. Bronchoscopy with cytology only appeared inflammatory cellularity (9% granulocytic polynuclears, 1% eosinophils, 5% monocytes, 27% alveolar macrophages, 52% lymphocytes with CD4/CD8 ratio of 0.25). Infectious etiology was ruled out through PCR, blood cultures and BAS citology. He was diagnosed of apalutamide-induced ILD, so he started endovenous metilpred-nisolone 1 mg/kg/day and switched to oral prednisone 60 mg/day for fifteen days, progressively reducing 7.5 mg per week until discontinued with rapid resolution of the dyspnea. CT reassessment two months after showed practical resolution of the pulmonary signs (Fig. 2B).

Currently both patients are undergoing follow-up observation with ADT treatment without progression and no respiratory symptoms. Apalutamide was no re-administered in both cases.

Drug-induced ILD is a serious condition that occurs in 3–5% of all cases of ILD ad it is associated with antineoplastic drugs like bleomycin, targeted drugs, immune checkpoint inhibitors or antiandrogens (bicalutamide, flutamide, goserelin, degarelix and apalutamide) in which it tends to occur during first year after starting treatment.^{4,5} In our cases, it manifested at 3 and 6 months respectively. Although cases of ILD have been described in the literature with gonadotropin releasing hormone agonist,⁴ in our reported cases we did not find a causal relationship with ILD since the patients continued treatment with ADT without recurrence of symptoms and with radiological improvement. The occurrence of ILD due to apalutamide has been described in adverse effects databases,^{4,5} but there are only a few cases reported in Asian patients.^{2,3} To the best of our knowledge these are the first two cases of apalutamide-induced ILD reported in European patients.

In conclusion, apalutamide-induced ILD is a rare side effect that must keep in mind due to its potential severity, so lung function should be monitored in patients treated with ARSi, especially during first year of therapy.

Authors' contributions

Rocío del Castillo-Acuña: Writing-review & editing. Ana Serradilla: Writing-review & editing. Fernando López-Campos: Writing-review & editing. Supervision. Felipe Couñago: Writingreview & editing. Supervision.

Conflict of interests

The authors state that they have no conflict of interests.




Fig. 1. Patient 1.(A) CT scan shows subpleural parenchymal bands, ground-glass opacities and bilateral consolidations in both lung fields at 3 months after started apalutamide. (B) CT scan at 3 months after discontinuing apalutamide, showed a significant improvement with resolution of previously described pulmonary signs.




Fig. 2. Patient 2. (A) CT scan shows bilateral patchy areas of ground-glass opacities with bronchiectasis at 6 months after started apalutamide. (B) CT scan at 2 months after discontinuing apalutamide, showed practical resolution of the pulmonary signs.

References

- 1. Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes A. Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:661. Available from: https://pubmed.ncbi.nlm.nih.gov/31150574/ [cited 20.10.23].
 Z. Kirishima F, Shigematsu Y, Kobayashi K. Interstitial lung disease induced by apalutamide therapy for castration-resistant prostate cancer: a report of a rare cise. IIII. Core Pop. 2023;5:152.5. Available form:
- report of a rare case. IJU Case Rep. 2022;5:153–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35509772 [cited 20.10.23].
- Kobe H, Tachikawa R, Masuno Y, Matsunashi A, Murata S, Hagimoto 3. H, et al. Apalutamide-induced severe interstitial lung disease: a report of two cases from Japan. Respir Investig. 2021;59:700-5. Available from: https://pubmed.ncbi.nlm.nih.gov/34144936/ [cited 20.10.23].
- 4. Wu B, Shen P, Yin X, Yu L, Wu F, Chen C, et al. Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System. Br J Clin Pharmacol. 2023;89:440-8. Available from: https://pubmed.ncbi.nlm.nih.gov/35349180/ [cited 20.10.23].
- Nawa H, Niimura T, Hamano H, Yagi K, Goda M, Zamami Y, et al. Evaluation of 5 potential complications of interstitial lung disease associated with antiandrogens using data from databases reporting spontaneous adverse effects. Front Pharmacol. 2021;12. Available from: https://pubmed.ncbi.nlm.nih.gov/34177574/ [cited 20.10.23].

Rocío del Castillo-Acuña^{a,*}, Ana Serradilla^b, Fernando López-Campos^c, Felipe Couñago^{d,e,f}

^a Department of Radiation Oncology, Hospital Universitario Punta de Europa, Algeciras, Spain

^b Department of Radiation Oncology, Complejo Hospitalario de Jaen, Jaen, Spain

^c Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain

^d Department of Radiation Oncology GenesisCare, Hospital San Francisco de Asís, Madrid, Spain

^e Department of Radiation Oncology GenesisCare, Hospital Vithas La Milagrosa, Madrid, Spain

^f Director Nacional Clínico y de Investigación, GenesisCare España, Madrid, Spain

Corresponding author.

E-mail address: rociodelcas@yahoo.es (R. del Castillo-Acuña).